InMode, which recently made its non-surgical Envision dry eye platform available to Australian eyecare professionals, will be exhibiting at two upcoming conferences, as well as hosting North American optometrist Dr Bruce Dornn for an Australian roadshow where he will discuss his experience the technology.
The company will be showcasing Envision at:
O=MEGA 23/4th World Congress of Optometry
8-10 September, Melbourne Convention and Exhibition Centre
InMode will be exhibiting and demonstrating the InMode Envision platform at the trade fair.
Stand number: A1
RANZCO Congress 2023
20-23 October, Perth Convention and Exhibition Centre
InMode will be exhibiting and demonstrating the InMode Envision platform in the trade fair.
Stand number: 27
Dr Bruce Dornn Australia tour
InMode will also be welcoming Dr Bruce Dornn to Australia. He’s a Canadian optometrist and early adopter of the Envision platform for dry eye four years ago.
He will be presenting at:
- QT Hotel Sydney, 16 October
- QT Hotel Melbourne, 17 October
“Envision has been a game changer for my practice as I can effectively treat the cause of dry eye disease with life-changing results, plus with Morpheus8 I can build an additional income stream by tightening the skin in the periorbital area and full face,” Dornn said.
Read more about Dornn’s experience with the Envision platform in this May 2023 interview with Insight.
CPD approval pending
For more information, RSVP, or to book a demonstration at any of the above events, contact:
Business Development Manager – Envision, InMode ANZ
0491 221 168 | firstname.lastname@example.org
Envision from InMode is a revolutionary eyecare platform featuring three technologies.
The Forma-I handpiece is the primary treatment on the platform and features bipolar RF to address the symptoms of dry eye disease caused by meibomian gland dysfunction (MGD) using controlled dermal heating to aid gland expression.
Envision’s secondary treatment is Lumecca-I, which InMode said delivers precise, targeted, intense pulsed light (IPL) procedures to treat inflammatory conditions associated with dry eye disease.
The third – and complementary – treatment is MORPHEUS8. It adopts fractional RF microneedling for complete face and body dermal resurfacing, tightening and subdermal remodelling.
More information can be found here.